Novo Nordisk invests DKK 2.1 billion in new insulin filling facility in Denmark, creating 450 new jobs

Novo Nordisk invests DKK 2.1 billion in new insulin filling facility in Denmark, creating 450 new jobs

Bagsværd, Denmark, 4 November 2015 – Novo Nordisk is investing 2.1 billion Danish kroner in a new 10,300 m2 facility in Hillerød, Denmark. The facility will produce medicines for the treatment of diabetes and obesity.

A groundbreaking ceremony marking the start of construction work will be held today, Wednesday 4 November, at the company's Hillerød site, attended by the mayor of Hillerød, Dorte Meldgaard.

The facility is expected to be operational in 2019 and will create 450 new production and engineering jobs in Hillerød, where Novo Nordisk already employs 1,900 people. Incorporating the latest state-of-the-art insulin production technology, the new insulin filling facility will ensure production capacity for existing and future products within diabetes.

"The investment in Hillerød underscores our long-term ambition to create and maintain jobs in Denmark. This year alone we have created 1,000 new jobs in Denmark, of which 500 are in production, primarily in Kalundborg and Hillerød," said Henrik Wulff, executive vice president and head of Product Supply, Novo Nordisk.

Today's groundbreaking event takes place from 3 to 4 pm at Brennum Park, Hillerød.

About Novo Nordisk in Hillerød
Established in 1992, the Hillerød site covers an area of about 1,650,000 m2, of which 90,000 m2 is used for production, research and development. The site houses a facility for device R&D and three production facilities: one for moulding and pre-assembly of components, one for filling, assembly and packaging of diabetes finished products and one for the production of active pharmaceutical ingredients for haemophilia products. Novo Nordisk has made ongoing investments in the site of approximately 350 million kroner per year on average.

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 40,300 people in 75 countries and markets its products in more than 180 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube

On-Demand Webinar

Leveraging A Medical Record-Enriched Patient Dataset for COVID-19 Research

You are invited to join a webinar that will explore the ways researchers can leverage this enriched dataset for important COVID-19 research. Sign up today for this informative webinar to learn how you can leverage one of the only medical record reviews solely using real-world data from hospitalized COVID-19 patients.

Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

New York's Covaxx has signed on with three South American nations to provide 140 million doses of its early-stage COVID-19 vaccine.

CureVac has tapped Wacker to help produce 100 million doses of its mRNA-based COVID-19 vaccine at its Amsterdam facility.